Member Info for Clenchedcheeks

Stas20. Are you for real?

"Where more serious value gets created" Like LUCY and BELL you mean?

Timing does indeed matter. We currently have equity in SALT and some potential in Guident. The shocks have disappeared off the face of the earth despite having spent tens of thousands producing prototypes. SALT may progress but then again it might not.

Some of us have been in here since outset and heard all the false promises re special dividends previously. It's about time they delivered.

How it's got to this I do not know.

You have products which are in demand yet the senior management go through cash like it's water. Where has it all gone? Even the vastly over rewarded senior management team can't have gone through this much.

18% per annum with the option to convert for what is a relatively small sums of money!

Some accurate H1 sales figures across the product range would be a start. I stress the word accurate.

Monday's a school day.

Re Lolly: Far from being an incubator, TEK has acted as Bank of Mum & Dad to its previous spinoffs, with little at the end to show for it.

The most accurate summary that I've read on here. That's exactly as it has been and as it still is.

And TEK (we've) sunk for more than $916,000 into it over the years!

Have the three of you considered writing your own column for a financial journal?

That'd be the same company that floated at 45 pence four years ago with products in demand but which would appear to have been run by an inept management team and board of directors.

Long standing shareholders will be relieved to know that the CEO Mr Rauker has managed to survive on a total a total salary and benefits package of $1.497m for the financial years ended 31st December 2021-23, an average of $499,000 per annum.

Re: nextdeal

You mean wow because they're down 98% since launch, or wow because they've almost run out of cash despite having made a huge raise a couple of months ago?

Extracts from H1 2024 results published on 26th September 2024:

.............................................

Demand for the new DISCOV-R™ portable oxygen concentrator, introduced to US market via a soft launch in June 2024, has been strong with every DISCOV-R™ unit manufactured in Q3 being sold. Full commercial launch of the DISCOV-R™ remains planned for the middle of Q4.

· Q4 sales target of $4.0m subject to timely receipt of Pricing Data Analysis and Coding (PDAC) codes to enable Durable Medical Equipment (DME) distributers to claim reimbursement from Medicare for sales of DISCOV-R and for the Company to finalise appropriate debt-based funding and invoice discounting to meet increasing working capital requirement arising from sales growth.

.........................................

Now we're told that DISCOV-R remains on track and is expected to launch towards the end of Q3 2025. The problem is that they have to get there and they burn so much money each month that they may not. How about senior management going without a salary for a few months to ease the burden, in particular the $0.5m per annum package for one person alone.

Market Cap is now £2m. Surely a competitor will make a bid.

Mr Rauker should consider taking a pay cut. His salary and benefits package in the year end accounts for 2023 was in excess of $0.5m yet sales were less than $1m in Q1 2025. There are companies in towns and cities throughout the UK which have higher sales yet their MD's aren't paid anything like that.

The September 2024 half year update quoted a Q4 2024 sales target of $4m. No mention of what they actually achieved.

The Q1 2025 sales figure is now quoted as $912,000 which represents a fraction of the above figure. That was pre the Trump tariff. How can your projections be so far out? Shocking misrepresentation in my opinion.

Surely at this market cap a competitor or someone in the sector will make a bid? The IP alone has to be worth many times the current share price.

We were told that the orders were there

The RNS dated 26th September 2024 when the share price was 12 pence included the following statement:

Current trading and outlook:

· Sales continue to grow and with (unaudited) Q3 sales of $1.6m, 20% up on H1 2024 and 40% up on Q2 2024.

· Strong sales to continue with the broader market acceptance of the X-PLOR® and the upcoming full release of its new patented DISCOV-R™ device.

· Demand for the new DISCOV-R™ portable oxygen concentrator, introduced to US market via a soft launch in June 2024, has been strong with every DISCOV-R™ unit manufactured in Q3 being sold. Full commercial launch of the DISCOV-R™ remains planned for the middle of Q4.

· Q4 sales target of $4.0m subject to timely receipt of Pricing Data Analysis and Coding (PDAC) codes to enable Durable Medical Equipment (DME) distributers to claim reimbursement from Medicare for sales of DISCOV-R and for the Company to finalise appropriate debt-based funding and invoice discounting to meet increasing working capital requirement arising from sales growth.

Robert Rauker, CEO, Belluscura plc, commented:

"We are delighted with the growth in sales and distribution over the past nine months for both the X-PLOR® and DISCOV-R™ portable oxygen concentrators. Whilst it has taken time to bring both products to market, and we are grateful for the patience of our shareholders, we now have two leading lightweight portable oxygen enrichment concentrators that meet the stringent requirements of the FDA, with the full commercial launch of DISCOV-R™ coming later in the year. We look forward to the remainder of 2024 and into 2025 with a real sense of confidence."

Here we are at close on 3rd April 2025 with a share price of 1.25 pence.

Yep, those sales figures prove how easy it is to spend other people's money because you sure wouldn't do it if it were your own.

The IP was worth more to TEK holders pre floatation than the residual value of TEK's current shareholding in the trading company. The same with BELL.

We need some exceptional Q1 sales figures early next month . Without them I fear this will continue to drift south.

Some Q4 2024 sales figures would have been nice, especially after the false dawn in September. I assume the figures weren't good as here we are less than a week away from April.

For those who've not already read it, this may be worth a read:

https://theoakbloke.substack.com/p/bell-y-aching-for-the-future-uscura

I wonder what happened to the 6,500 DISCOV-R orders referred to in the August 2023 RNS?

https://polaris.brighterir.com/public/belluscura/news/json_news/story/r742ozr

Thanks Red, I agree it's very encouraging.

My only lingering doubt about Guident's proposition is, why haven't Tesla or Waymo come knocking?

Agreed. Complete disregard for shareholders.